1. Which patients should be operated on after induction chemotherapy for N2 non–small cell lung cancer? Analysis of a 7-year experience in 175 patients 
Alessandro Stefani, MD, Marco Alifano, MD, Antonio Bobbio, MD, Madalina Grigoroiu, MD, Rami Jouni, MD, Pierre Magdeleinat, MD, Jean-Francois Regnard, MD 
The Journal of Thoracic and Cardiovascular Surgery 
Volume 140, Issue 2, Pages (August 2010)
DOI: /j.jtcvs
Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

2. Figure 1
A, Survival by clinical response to chemotherapy. SD, Stable disease; OR, objective response. Five-year survival was 42% and 10% for responders and nonresponders, respectively. Median survival time was 50.8 and 19.0 months (P < .01). B, Survival by pathologic mediastinal downstaging. Five-year survival was 45% and 22% for patients with downstaged and persistent N2 disease, respectively. Median survival time was 50.9 and 24.9 months (P < .01).
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )
Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions